Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,300.60 +53.92 (+1.03%) Dow
39,825.73 +267.62 (+0.68%) Nasdaq
16,727.05 +215.87 (+1.31%) Bitcoin USD
65,308.32 +3,946.52 (+6.43%) CMC Crypto 200
1,373.32 +105.37 (+8.31%)
LLY Jan 2026 920.000 call
| Previous close | 83.05 |
| Open | 83.05 |
| Bid | 91.40 |
| Ask | 95.35 |
| Strike | 920.00 |
| Expiry date | 2026-01-16 |
| Day's range | 83.05 - 83.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 32 |
ZacksBiogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
BenzingaEli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which contains tirzepatide. As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly’s branding to promote its products. In addition to the financial settlement, Totality Medispa is required to take corrective actions, including ensuring that any compounded tirzepatid
ZacksShould You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
